FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Go back to FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis| Regeneron (NASDAQ: REGN) | Delayed: 789.45 +14.84 (1.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $774.61 | 52 Week High | $592.36 | |||
| Open | $781.18 | 52 Week Low | $325.35 | |||
| Day High | $789.99 | P/E | 207.20 | |||
| Day Low | $774.78 | EPS | $3.81 | |||
| Volume | 702,816 | |||||
